Revenio Group Oyj (REVX.F) Stock Overview
Provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
REVX.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Revenio Group Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €16.41 |
| 52 Week High | €28.50 |
| 52 Week Low | €16.41 |
| Beta | 0.85 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -52.84% |
| 5 Year Change | -78.26% |
| Change since IPO | 1,290.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| REVX.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -0.9% |
| 1Y | n/a | -18.9% | 19.4% |
Return vs Industry: Insufficient data to determine how REVX.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how REVX.F performed against the US Market.
Price Volatility
| REVX.F volatility | |
|---|---|
| REVX.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: REVX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine REVX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 246 | Jouni Toijala | www.reveniogroup.fi |
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images.
Revenio Group Oyj Fundamentals Summary
| REVX.F fundamental statistics | |
|---|---|
| Market cap | US$384.27m |
| Earnings (TTM) | US$17.90m |
| Revenue (TTM) | US$126.49m |
Is REVX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| REVX.F income statement (TTM) | |
|---|---|
| Revenue | €111.05m |
| Cost of Revenue | €33.38m |
| Gross Profit | €77.67m |
| Other Expenses | €61.96m |
| Earnings | €15.71m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Sep 08, 2026
| Earnings per share (EPS) | 0.59 |
| Gross Margin | 69.94% |
| Net Profit Margin | 14.15% |
| Debt/Equity Ratio | 5.1% |
How did REVX.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/14 10:56 |
| End of Day Share Price | 2026/05/27 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revenio Group Oyj is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pia Rosqvist-Heinsalmi | Carnegie Investment Bank AB |
| Daniel Lepisto | Danske Bank |
| Pia Rosqvist-Heinsalmi | DNB Carnegie |